Upgrade your membership to see all of the expert analysis we have published on CPRX now!
Decisive Sell Signal Triggered by Considerable Loss on Heavy Volume - Monday, January 23, 2023
Catalyst Pharma Inc (CPRX -$6.04 or -29.04% to $14.76) gapped down today and violated its 50-day moving average (DMA) line ($17.61) with a considerable loss backed by +642% above average volume triggering a decisive technical sell signal. When any stock suffers its largest loss ever backed by the heaviest volume it is considered a technical sell signal. Only a prompt rebound above the 50 DMA line would help its outlook improve.
CPRX finished strong after highlighted in yellow with new pivot point cited based on its 11/11/22 high in the 11/22/22 mid-day report (read here). It was shown in this FSU section on 1/11/23 with an annotated graph under the headline, "Making Gradual Progress Hitting Another New High".
It has an Earnings Per Share rating of 99. Recently it reported Sep '22 quarterly earnings +86% on +59% sales revenues versus the year ago period, its 4th consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) growth has been strong since turning profitable in FY '19.
The Medical-Biomed/Biotech industry group is currently ranked 17th on the 197 Industry Groups list, a reassuring sign concerning the L criteria. It has only 88.5 million shares in the public float. The number of top-rated funds owning its shares rose from 311 in Sep '21 to 412 in Dec '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.3 is an unbiased indication its shares have been under accumulation over the past 50 days.
Making Gradual Progress Hitting Another New High - Wednesday, January 11, 2023
Catalyst Pharma Inc (CPRX +$0.08 or +0.41% to $19.81) touched a new 52-week high today Its 50-day moving average (DMA) line ($16.84) defines near-term support to watch on pullbacks..
CPRX finished strong after highlighted in yellow with new pivot point cited based on its 11/11/22 high in the 11/22/22 mid-day report (read here). It was shown in this FSU section on 12/20/22 with an annotated graph under the headline, "Powerful Rally to New High for Catalyst".
It has an Earnings Per Share rating of 99. Recently it reported Sep '22 quarterly earnings +86% on +59% sales revenues versus the year ago period, its 4th consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) growth has been strong since turning profitable in FY '19.
The Medical-Biomed/Biotech industry group is currently ranked 28th on the 197 Industry Groups list, a reassuring sign concerning the L criteria. It has only 88.5 million shares in the public float. The number of top-rated funds owning its shares rose from 311 in Sep '21 to 405 in Dec '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.2 is an unbiased indication its shares have been under accumulation over the past 50 days.
Powerful Rally to New High for Catalyst - Tuesday, December 20, 2022
Catalyst Pharma Inc (CPRX +$2.19 or +13.35% to $18.60) posted a big gain today with volume +79% above average, quickly rallying back above its pivot point and above its "max buy" level to a new all-time high. Its color code was changed to green. It recently found prompt support near the prior high and well above its 50-day moving average (DMA) line ($15.26).
CPRX finished strong after highlighted in yellow with new pivot point cited based on its 11/11/22 high in the 11/22/22 mid-day report (read here). It rallied from a 9-week cup-with-handle consolidation for a new 52-week high with a big gain backed by +90% above average volume triggering a technical buy signal. The volume-driven gain provided a reassurance that institutional buying demand was lurking. It was shown in this FSU section on 11/22/22 with an annotated graph under the headline, "Breakout From Cup-With-Handle With 90% Above Average Volume".
It has an Earnings Per Share rating of 99. Recently it reported Sep '22 quarterly earnings +86% on +59% sales revenues versus the year ago period, its 4th consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) growth has been strong since turning profitable in FY '19.
The Medical-Biomed/Biotech industry group is currently ranked 32nd on the 197 Industry Groups list, a reassuring sign concerning the L criteria. It has only 88.5 million shares in the public float. The number of top-rated funds owning its shares rose from 311 in Sep '21 to 376 in Sep '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.2 is an unbiased indication its shares have been under accumulation over the past 50 days.
Chart courtesy of www.stockcharts.com
Breakout From Cup-With-Handle With 90% Above Average Volume - Tuesday, November 22, 2022
Catalyst Pharma Inc (CPRX +$1.95 or +12.53% to $17.51) finished strong after highlighted in yellow with new pivot point cited based on its 11/11/22 high in then earlier mid-day report (read here). It rallied from a 9-week cup-with-handle consolidation for a new 52-week high with a big gain today backed by +90% above average volume triggering a technical buy signal. The volume-driven gain provided a fresh reassurance that institutional buying demand is still lurking.
CPRX showed resilience since dropped from the Featured Stocks list on 9/23/22. It was last shown in this FSU section on 9/08/22 with an annotated graph under the headline, "Hit a New High After a 4-Week Tight Pattern of Closes".
It has an Earnings Per Share rating of 99. Recently it reported Sep '22 quarterly earnings +86% on +59% sales revenues versus the year ago period, its 4th consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) growth has been strong since turning profitable in FY '19.
The Medical-Biomed/Biotech industry group is currently ranked 18th on the 197 Industry Groups list, a reassuring sign concerning the L criteria. It has only 87.4 million shares in the public float. The number of top-rated funds owning its shares rose from 311 in Sep '21 to 370 in Sep '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.5 is an unbiased indication its shares have been under accumulation over the past 50 days.
Chart courtesy of www.stockcharts.com
Hit a New High After a 4-Week Tight Pattern of Closes - Thursday, September 8, 2022
Catalyst Pharma Inc (CPRX +$0.38 or +2.56% to $15.25) was highlighted in yellow with pivot point cited based on its 8/23/22 high plus 10 cents in the earlier mid-day report (read here). It hit a new all-time high with +36% above average volume behind today's gain after a very tight 4-week consolidation. It went a little longer after it already formed a "3-weeks tight" with a few weekly changes of less than 2%. For a valid technical buy signal, the minimum volume threshold behind a technical breakout is +40% above average. It already rallied considerably in the weeks before forming its new advanced base pattern. Confirming volume-driven gains might provide greater reassurance that heavy institutional buying demand is still lurking. In fact, the biggest market winners usually had much heavier than normal volume behind their breakouts.
It has an Earnings Per Share rating of 98. CPRX reported Jun '22 quarterly earnings +75% on +46% sales revenues versus the year ago period, its 3rd consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) growth has been strong since turning profitable in FY '19.
It has an Earnings Per Share rating of 98. CPRX reported Jun '22 quarterly earnings +75% on +46% sales revenues versus the year ago period, its 3rd consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) growth has been strong since turning profitable in FY '19.
The Medical-Biomed/Biotech industry group is currently ranked 4th on the 197 Industry Groups list, a reassuring sign concerning the L criteria. It has only 84.7 million shares in the public float. The number of top-rated funds owning its shares rose from 311 in Sep '21 to 358 in Jun '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 2.6 is an unbiased indication its shares have been under accumulation over the past 50 days.
Chart courtesy of www.stockcharts.com
